PGIM India Healthcare Fund
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Growthvine rating: 1/5 — ranked #82 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹11.87 (as of 2026-10-01) |
|---|
| AUM | ₹125 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Anandha Padmanabhan Anjeneyan |
|---|
| Exit load | 0.5% for redemption within 90 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −14.58% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 108.7% of NIFTY Pharma's upside and 103.9% of its downside.
Market cap allocation
| Large cap | 34.5% |
|---|
| Mid cap | 29.8% |
|---|
| Small cap | 35.6% |
|---|
Concentration
| Top 5 holdings | 40.2% |
|---|
| Top 10 holdings | 59.6% |
|---|
| Total holdings | 31 |
|---|
Top holdings
- Divis Laboratories Ltd. — 10.9%
- Sun Pharmaceutical Industries Ltd. — 10.7%
- Torrent Pharmaceuticals Ltd. — 8.9%
- Clearing Corporation of India Ltd. — 5.8%
- Max Healthcare Institute Limited — 5.0%
- Ajanta Pharma Ltd. — 4.8%
- Manipal Health Enterprises Limited — 4.1%
- Mankind Pharma Limited — 4.1%
- RUBICON RESEARCH LIMITED — 4.0%
- Dr. Lal Pathlabs Limited — 3.9%
Top sectors
- Pharma & Biotech — 63.3%
- Healthcare — 25.7%
- Cash — 5.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 20.6% | Q1 (Top) | #3 of 76 |
| 2025 | −2.7% | Q3 | #44 of 69 |